<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pharmacol</journal-id><journal-title-group><journal-title>Clinical Pharmacology : Advances and Applications</journal-title></journal-title-group><issn pub-type="epub">1179-1438</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23723721</article-id><article-id pub-id-type="pmc">3666910</article-id><article-id pub-id-type="doi">10.2147/CPAA.S40401</article-id><article-id pub-id-type="publisher-id">cpaa-5-013</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian
carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brueseke</surname><given-names>Taylor J</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tewari</surname><given-names>Krishnansu S</given-names></name><xref ref-type="corresp" rid="c1-cpaa-5-013"/></contrib><aff id="af1-cpaa-5-013">Department of Obstetrics and Gynecology, Division of Gynecologic Oncology,
University of California, Irvine, Orange, CA, USA</aff></contrib-group><author-notes><corresp id="c1-cpaa-5-013">Correspondence: Krishnansu S Tewari, Department of Obstetrics and
Gynecology, Division of Gynecologic Oncology, University of California, Irvine, 101 The City Drive
South, Building 56, Suite 800, Orange, CA 92868, USA, Tel +1 714 456 8020, Fax +1
714 456 6332, Email <email>ktewari@uci.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>23</day><month>5</month><year>2013</year></pub-date><volume>5</volume><issue>Suppl 1</issue><fpage>13</fpage><lpage>19</lpage><permissions><copyright-statement>&#x000a9; 2013 Brueseke and Tewari, publisher and licensee Dove Medical Press
Ltd</copyright-statement><copyright-year>2013</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the
original work is properly cited.</license-p></license></permissions><abstract><p>Ovarian cancer is the most deadly gynecologic cancer, with 15,000 anticipated deaths within the
United States alone in 2012, and new treatment strategies are needed. Ovarian cancer tumors are
known to host an immunosuppressive microenvironment. This suppression may be reversible via
activation of the innate immune response. Toll-like receptor 8 activates innate immunity while
simultaneously inhibiting the effects of regulatory T cells within the ovarian cancer tumors.
VTX-2337 is a novel small molecule ligand of Toll-like receptor 8 and is currently the subject of a
Phase II randomized, double-blind, placebo-controlled trial Gynecologic Oncology Group (GOG)-3003
for patients with recurrent platinum-resistant ovarian cancer. We look forward to the results of
this trial as support for the paradigm of process therapy in the treatment of ovarian cancer.</p></abstract><kwd-group><kwd>immunotherapy</kwd><kwd>ovarian cancer</kwd><kwd>Gynecology Oncology Group partners</kwd><kwd>VTX 2237</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Ovarian cancer is the deadliest gynecological cancer, with 22,000 new cases and 15,000 deaths
anticipated within the United States in 2012.<xref ref-type="bibr" rid="b1-cpaa-5-013">1</xref>
Despite years of intense research, the etiology of this disease remains unknown. There is currently
no consistent early symptom or screening test, and consequently, most patients present with
advanced-stage disease. Traditional therapy for ovarian cancer has included maximal cytoreductive
surgery followed by cytotoxic chemotherapy with a platinum/taxane-based regimen. While most ovarian
cancer is initially chemosensitive, recurrence of the disease is common and may be categorized as
either platinum-sensitive or refractory. Current treatment regimens for platinum resistant
recurrence include single agent paclitaxel, liposomal doxorubicin, or topotecan. Outcomes with these
regimens are poor, with significant potential toxicity, thus, new treatment modalities are needed.
The Gynecologic Oncology Group (GOG) is actively pursuing alternative treatment regimens including
intraperitoneal chemotherapy, dose-dense paclitaxel, and anti-angiogenesis therapy. To date, there
have been four positive Phase III clinical trials demonstrating improved progression-free survival
with the anti-angiogenesis monoclonal antibody bevacizumab, in patients with ovarian cancer.<xref ref-type="bibr" rid="b2-cpaa-5-013">2</xref>&#x02013;<xref ref-type="bibr" rid="b5-cpaa-5-013">5</xref></p><p>Additional research has focused on immunotherapy and includes:<xref ref-type="bibr" rid="b6-cpaa-5-013">6</xref> administration of tumor-directed antibodies,<xref ref-type="bibr" rid="b7-cpaa-5-013">7</xref>,<xref ref-type="bibr" rid="b8-cpaa-5-013">8</xref> administration of
immune-stimulatory cytokines, <xref ref-type="bibr" rid="b9-cpaa-5-013">9</xref>,<xref ref-type="bibr" rid="b10-cpaa-5-013">10</xref> peptide cancer vaccines, adoptive cell
transfers,<xref ref-type="bibr" rid="b11-cpaa-5-013">11</xref> depletion of regulatory T cells, and
dysfunctional immune cosignaling blockade. Each of these has met with modest results. Further
insights were gained with the mapping of the ovarian cancer genome atlas,<xref ref-type="bibr" rid="b12-cpaa-5-013">12</xref> which elucidated multiple aberrant cellular pathways within ovarian
tumor cells. These discoveries have generated interest in specific pathway inhibition including:
poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors,<xref ref-type="bibr" rid="b13-cpaa-5-013">13</xref>,<xref ref-type="bibr" rid="b14-cpaa-5-013">14</xref>
anti-folic acid receptor inbitors,<xref ref-type="bibr" rid="b15-cpaa-5-013">15</xref> heat shock
protein 90 inhibition,<xref ref-type="bibr" rid="b16-cpaa-5-013">16</xref> gamma secretase
inhibitors,<xref ref-type="bibr" rid="b17-cpaa-5-013">17</xref> and aurora kinase inhibtors.<xref ref-type="bibr" rid="b18-cpaa-5-013">18</xref> However, tumors often possess multiple aberrant
pathways with a high degree of cross talk between signaling cascades, and thus, therapeutics
directed at pathway inhibition may not have optimal success if the complexity of the pathway is not
fully recognized or if a given patient does not possess the targeted aberrant pathway.</p><p>Reversing the process of tumor-induced immunosuppression is a promising alternative in
immunotherapy. Ovarian cancer tumors are known to contain tumor-infiltrating lymphocytes (including
T cells and dendritic cells [DCs]). These lymphocytes, however, are quiescent and do
not readily attack tumor cells. The reason for this is multifactorial; however, regulatory T cells
and inert DCs are postulated to play a role in the creation of this immunosuppression. Activation of
Toll-like receptors (TLRs) holds potential for the reversal of this immunosuppressive
microenvironment. As mentioned in the awarding of the 2011 Nobel Prize in Medicine or Physiology,
TLRs and DCs are the link between innate and adaptive immunity,<xref ref-type="bibr" rid="b19-cpaa-5-013">19</xref> thus, triggering the innate immune response in ovarian cancer tumors
may result in activation of cytotoxic T cells and natural killer cells and in the elimination of
ovarian cancer cells.</p></sec><sec><title>Innate immunity</title><p>Ralph Steinmann, Bruce Beutler, and Jules Hoffmann were awarded the 2011 Nobel Prize in Medicine
or Physiology for discovering the roles that DCs and TLRs play as the gatekeepers of innate
immunity. The innate immune system is the first line of defense against foreign organisms and
includes natural killer cells, mast cells, eosinophils, basophils, physical barriers, and phagocytic
cells, including DCs, macrophages, and neutrophils. DCs possess TLRs, which were the first
pathogen-associated pattern-recognition receptors to be discovered. Activation of these receptors by
exposure to foreign molecules results in the activation of a signal cascade, with multiple
downstream effects.<xref ref-type="bibr" rid="b20-cpaa-5-013">20</xref> Upon activation, DCs
increase their production of major histocompatibility complex (MHC) class II molecules and migrate
to draining lymph nodes, where they present antigens to na&#x000ef;ve T cells. The presentation of
antigens via MHC class II molecules to T helper cells type 1 and 2 results in the activation of the
adaptive immune response, with clonal expansion of T cells and the activation of B cell-mediated
antibody secretion.</p></sec><sec><title>Tumor microenvironment</title><p>Tumor-infiltrating lymphocytes were described in the microenvironment of ovarian cancer as early
as 1988.<xref ref-type="bibr" rid="b21-cpaa-5-013">21</xref> The types of lymphocytes present
include CD8+ T cells, macrophages, a relatively low concentration of natural killer cells, B
cells, polymorphonuclear cells, and rare mast cells.<xref ref-type="bibr" rid="b22-cpaa-5-013">22</xref> Significantly, the presence of tumor-infiltrating lymphocytes is associated with improved
overall survival.<xref ref-type="bibr" rid="b23-cpaa-5-013">23</xref>,<xref ref-type="bibr" rid="b24-cpaa-5-013">24</xref> However, these lymphocytes do not actively target ovarian cancer
cells. Rather, an immunosuppressive microenvironment is present within the tumor. Active evasion of
the immune response involves at least two cell types: (1) CD4+ CD25+ T cells (T
regulatory cells [Tregs]), and (2) CD11c + MCH-II myeloid DCs (mDCs), which
are the most abundant subset of leukocytes in the solid ovarian cancer microenvironment.<xref ref-type="bibr" rid="b25-cpaa-5-013">25</xref> Recent research has exploded regarding the role and
function of Tregs<xref ref-type="bibr" rid="b6-cpaa-5-013">6</xref>,<xref ref-type="bibr" rid="b7-cpaa-5-013">7</xref>,<xref ref-type="bibr" rid="b24-cpaa-5-013">24</xref>,<xref ref-type="bibr" rid="b26-cpaa-5-013">26</xref>&#x02013;<xref ref-type="bibr" rid="b32-cpaa-5-013">32</xref> and suggests that Tregs actively induce cytotoxic T cell anergy in at least two ways: (1)
direct cell-to-cell contact inhibition, and (2) humoral inhibition, including the downregulation of
interleukin-2. The presence of Tregs has been associated with poor prognosis. In one study,
individuals with the highest Treg counts per high-powered field of ovarian cancer tumor tissue had a
25-fold higher death hazard ratio (95% CI 6.8&#x02013;92.1)<xref ref-type="bibr" rid="b33-cpaa-5-013">33</xref> compared with those with the lowest Treg cell counts, even after
controlling for the stage of disease and surgical debulking. Additionally, mDCs have recently been
shown to actively inhibit T cell antitumor activity by expressing functional levels of the
immunosuppressive proteins PD-L1.<xref ref-type="bibr" rid="b34-cpaa-5-013">34</xref></p></sec><sec><title>Toll-like receptors</title><p>We believe that TLRs may hold the key to reversing this immunosuppressive microenvironment. TLRs
constitute a family of highly conserved pattern-recognition receptors (see <xref ref-type="table" rid="t1-cpaa-5-013">Table 1</xref>).<xref ref-type="bibr" rid="b35-cpaa-5-013">35</xref> Ten unique
TLRs have been characterized in humans. Of these, TLRs 1, 2, 4, 5, and 6 are expressed on the cell
membrane, while TLRs 3, 7, 8, and 9 are expressed within the endolysosomal compartmental
pathway.<xref ref-type="bibr" rid="b36-cpaa-5-013">36</xref>&#x02013;<xref ref-type="bibr" rid="b38-cpaa-5-013">38</xref> TLRs detect a number of different foreign molecules including: double
stranded deoxyribonucleic acid (DNA) (TLR3), lipopolysaccharides (TLR4), flagellin (TLR5),
single-stranded viral ribonucleic acid (RNA) (TLR7/8), and unmethylated CpG sites of DNA of bacteria
and viruses (TLR9).<xref ref-type="bibr" rid="b39-cpaa-5-013">39</xref> TLRs are expressed broadly
on hematopoietic cells, including DCs, plasma cells, monocytes, and B cells.<xref ref-type="bibr" rid="b30-cpaa-5-013">30</xref>,<xref ref-type="bibr" rid="b35-cpaa-5-013">35</xref>,<xref ref-type="bibr" rid="b40-cpaa-5-013">40</xref>,<xref ref-type="bibr" rid="b41-cpaa-5-013">41</xref></p><p>TLR activation induces the expression of selectins, chemokines, and chemokine receptors, the
combination of which regulates migration of inflammatory cells).<xref ref-type="bibr" rid="b42-cpaa-5-013">42</xref>,<xref ref-type="bibr" rid="b43-cpaa-5-013">43</xref> As reviewed by
Smits et al,<xref ref-type="bibr" rid="b31-cpaa-5-013">31</xref> the administration of TLR7/8
agonists results in the secretion of multiple proinflammatory Th1-type cytokines, including tumor
necrosis factor (TNF)-alpha, interleukins 1, 6, and 8, interferon-inducible protein 10, monocyte
chemotactic protein 1, interleukin 12p40, interleukin-12p70, and interleukin 18. The molecular
pathways in TLR signaling have previously been reviewed.</p><p>TLR7 is the therapeutic target of imiquimod, which has been used successfully in the treatment of
skin cancers.<xref ref-type="bibr" rid="b44-cpaa-5-013">44</xref>&#x02013;<xref ref-type="bibr" rid="b46-cpaa-5-013">46</xref> Given that TLR9 is expressed predominantly in B cells, it is
currently being explored in clinical trials for cutaneous lymphoma<xref ref-type="bibr" rid="b47-cpaa-5-013">47</xref> and leukemia.<xref ref-type="bibr" rid="b48-cpaa-5-013">48</xref></p><p>TLR8 is unique in the TLR family: the activation of TLR8 has a direct inhibitory effect on
Tregs.<xref ref-type="bibr" rid="b49-cpaa-5-013">49</xref> The exact mechanism for this is unknown;
however, Tregs express TLR8,<xref ref-type="bibr" rid="b50-cpaa-5-013">50</xref> and the ability of
TLR8 to reverse Treg inhibition is dendritic cell independent.<xref ref-type="bibr" rid="b31-cpaa-5-013">31</xref> TLR8 also likely has direct and indirect activating effects on
natural killer cells, causing them to produce interferon-gamma.<xref ref-type="bibr" rid="b40-cpaa-5-013">40</xref>,<xref ref-type="bibr" rid="b51-cpaa-5-013">51</xref>,<xref ref-type="bibr" rid="b52-cpaa-5-013">52</xref> The overall result of TLR8 activation is robust
enhancement of the innate immune response. Additionally, TLR8 receptors have been demonstrated to
have variable expression within epithelial ovarian cancer tumors.<xref ref-type="bibr" rid="b53-cpaa-5-013">53</xref></p></sec><sec><title>VTX-2337</title><p>The unique ability of TLR8 to reverse Treg immunosuppression and augment immunity in the tumor
microenvironment makes it an ideal target for ovarian cancer therapy. VTX-2337 is a synthetic
small-molecule agonist that is specific to TLR8, with a molecular weight of 458.6 Daltons and a
molecular structure based on a 2-aminobenzazepine core. A recently published in vitro study<xref ref-type="bibr" rid="b40-cpaa-5-013">40</xref> using TLR-transfected human embryonic kidney cells
showed that VTX-2337 selectively activates TLR8. The same study showed that VTX-2337 has the ability
to augment the immune response on multiple levels (<xref ref-type="fig" rid="f1-cpaa-5-013">Figure
1</xref>): it induces mDCs and monocytes to produce high levels of interleukin-12 and TNF-alpha. It
directly stimulates natural killer cells to produce interferon-gamma and increases their lytic
activity. Furthermore, VTX-2337 augments antibody-dependent cell-mediated cytotoxity. This process
works synergistically with standard chemotherapy. Contrary to the traditionally immunosuppressive
effects of most systemic cytotoxic chemotherapy, doxorubicin has been reported to increase the tumor
cell surface exposure of calreticulin and the internalization of tumor cell antigens by phagocytic
DCs.<xref ref-type="bibr" rid="b54-cpaa-5-013">54</xref>,<xref ref-type="bibr" rid="b55-cpaa-5-013">55</xref> Furthermore, dying cancer cells have been shown to release high-mobility group box 1
protein, a ligand for TLR4 that has been reported to synergize with TLR8 to activate DCs and prime
T-cell response.<xref ref-type="bibr" rid="b40-cpaa-5-013">40</xref> Therefore, VTX-2337 has the
potential to induce robust activation of the innate and adaptive immune response.</p><p>A Phase I clinical trial (NTC00688415), sponsored by VentiRx Pharmaceuticals (Seattle, WA, USA),
found VTX-2337 to be well tolerated and to have dose-dependent pharmacologic activity.<xref ref-type="bibr" rid="b56-cpaa-5-013">56</xref> As presented by Cohen et al<xref ref-type="bibr" rid="b56-cpaa-5-013">56</xref> at the American Society of Clinical Oncology (ASCO) 2011 meeting, the
inclusion criteria for this study were: (1) locally advanced or metastatic solid tumors or lymphoma,
and (2) Eastern Cooperative Oncology Group (ECOG) performance status of 0&#x02013;1. The exclusion
criteria were: (1) anticancer therapy within 2 weeks, (2) immunosuppressive therapy within 2 weeks,
and (3) active autoimmune disease. In this study, VTX-2337 was administered to 33 patients with
advanced solid tumors (the most common histologies were colorectal cancer, pancreatic cancer, and
melanoma), using a modified Fibonacci dose escalation scheme. Eight cohorts of 3&#x02013;8 patients
received doses from 0.1 mg/m<sup>2</sup> to 3.8 mg/m<sup>2</sup>. The median age of the patients was
65 years. There was an average of 3.1 years between the time of diagnosis and study entry. The most
common drug-related adverse events were grade 1&#x02013;2 injection site reaction (85%),
chills (58%), fever (42%), and flu-like symptoms (24%). Grade 3 hypotension
occurred in 1/6 patients and was the only dose-limiting toxicity. The primary outcome measures were
safety and the identification of dose-limiting toxicities and pharmacokinetics. The secondary
outcome measures were the identification of pharmacodynamics and mean toxic dose. The results showed
that the plasma levels of multiple immune mediators (including granulocyte colony-stimulating factor
[G-CSF], monocyte chemotactic protein [MCP]- 1, macrophage
inflammatory protein [MIP]1-beta, and TNF-alpha) were increased. As measured by the
Response Evaluation Criteria in Solid Tumors (RECIST) criteria, 25% of patients demonstrated
disease stabilization at 8 weeks.</p></sec><sec><title>VTX-2337 and ovarian cancer</title><p>Two clinical trials are currently investigating VTX-2337 in patients with ovarian cancer.
GOG-9925 (study chair BJ Monk) is a Phase I trial undergone in collaboration with the National
Cancer Institute, NCT01294293,<xref ref-type="bibr" rid="b57-cpaa-5-013">57</xref> evaluating the
side-effect profile and best dose of VTX-2337 and liposomal doxorubicin, in patients with persistent
or recurrent ovarian epithelial, fallopian tube, or peritoneal cancer. The primary outcomes are
first-cycle dose-limiting toxicity and the frequency/severity of toxicities. The secondary outcome
measures are immune activation and identification of the pharmacokinetics of VTX-2337 and pegylated
liposomal doxorubicin. Enrollment criteria include measurable disease by RECIST 1.1, or detectable
disease by CA-125 measurement, or other solid abnormalities on radiographic imaging. Enrolled
patients have one prior platinum-based chemotherapeutic regimen and recurrence of disease within a
12-month platinum-free interval and do not have evidence of central nervous system (CNS) metastasis.
This multicenter, dose-escalating study enrolled patients from April 2011 to June 2012.<xref ref-type="bibr" rid="b57-cpaa-5-013">57</xref> No results have yet been published from this
trial.</p><p>A Phase II randomized, double-blind, placebo-controlled study is also now underway. Known as GOG
Partners-3003 (study chair BJ Monk), NCT01666444 this trial is sponsored by VentiRx Pharmaceuticals
in collaboration with the GOG partners and enrolls patients with recurrent or persistent
platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, with
measurable disease by RECIST 1.1 criteria and at least one target lesion. <xref ref-type="fig" rid="f2-cpaa-5-013">Figure 2</xref> shows a schema of the trial structure: the investigational arm
is VTX-2337 plus standard regimen pegylated liposomal doxorubicin (PLD). The reference arm is
placebo plus standard regimen PLD. Patients who have previously been treated with VTX-2337,
doxorubicin, PLD, or other anthracycline, patients receiving immunosuppressive therapy for any
reason, and patients with active autoimmune disease are excluded from this study. 3.0
mg/m<sup>2</sup> of VTX-2337 or placebo will be administered as a subcutaneous injection on days 3,
10, and 17 of the first four 28-day treatment cycles and thereafter, on cycle day 3 only. The
primary outcome will be overall survival, with a planned analysis to occur approximately 15 months
after the last patient is enrolled. Secondary outcomes will be the frequency and nature of
side-effects of VTX-2337 and progression-free survival using Immune Related Response Evaluation
Criteria in Solid Tumors. CA-125 measurements will be required to be normal for diagnosis of
complete response. Progression will be assessed at week 12 and at 8-week intervals thereafter.
Exploratory objectives include the assessment of the effect of TLR8 polymorphisms and immune cell
subsets (as measured by immunohistochemistry in primary tumor tissue) on clinical outcomes, such as
overall survival, progression-free survival, and overall response rate.<xref ref-type="bibr" rid="b58-cpaa-5-013">58</xref></p></sec><sec><title>Conclusion</title><p>In conclusion, ovarian cancer remains a deadly disease, and new therapeutic approaches are
needed. The immunosuppressive microenvironment present in ovarian tumors represents a pathologic
process that is a prime target for novel therapies. Indeed, the 2011 Nobel Prize in Medicine or
Physiology highlights that TLRs are the gateway to activating the innate immune response, and it
appears that TLR8 ligands are in a unique position to augment the current treatment of patients with
ovarian cancer. Novel immunotherapeutic strategies and manipulation of the micro-enviroment may hold
the key to future success in ovarian cancer therapy.</p></sec></body><back><fn-group><fn id="fn1-cpaa-5-013"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-cpaa-5-013"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Naishadham</surname><given-names>D</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2012</article-title><source>CA Cancer J
Clin</source><year>2012</year><volume>62</volume><issue>1</issue><fpage>10</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">22237781</pub-id></element-citation></ref><ref id="b2-cpaa-5-013"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perren</surname><given-names>TJ</given-names></name><name><surname>Swart</surname><given-names>AM</given-names></name><name><surname>Pfisterer</surname><given-names>J</given-names></name><etal/></person-group><collab>ICON7 Investigators</collab><article-title>A phase 3 trial of bevacizumab in
ovarian cancer</article-title><source>N Engl J
Med</source><year>2011</year><volume>365</volume><issue>26</issue><fpage>2484</fpage><lpage>2496</lpage><pub-id pub-id-type="pmid">22204725</pub-id></element-citation></ref><ref id="b3-cpaa-5-013"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>RA</given-names></name><name><surname>Brady</surname><given-names>MF</given-names></name><name><surname>Bookman</surname><given-names>MA</given-names></name><etal/></person-group><collab>Gynecologic Oncology Group</collab><article-title>Incorporation of
bevacizumab in the primary treatment of ovarian cancer</article-title><source>New Engl J
Med</source><year>2011</year><volume>365</volume><issue>26</issue><fpage>2473</fpage><lpage>2483</lpage><pub-id pub-id-type="pmid">22204724</pub-id></element-citation></ref><ref id="b4-cpaa-5-013"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name><name><surname>Hilpert</surname><given-names>F</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><etal/></person-group><collab>AURELIA Investigators</collab><article-title>AURELIA: a randomized phase III
trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent
ovarian cancer (OC)</article-title><source>J Clin
Oncol</source><year>2012</year><volume>30</volume><issue>Supplement 18</issue><comment>Available
from: <ext-link ext-link-type="uri" xlink:href="http://meeting.ascopubs.org/cgi/content/abstract/30/18_suppl/LBA5002?sid=799bb046-3aad-4937-a1ff-10b69d3f9782">http://meeting.ascopubs.org/cgi/content/abstract/30/18_suppl/LBA5002?sid=799bb046-3aad-4937-a1ff-10b69d3f9782</ext-link></comment><date-in-citation>Accessed
March 13, 2013</date-in-citation></element-citation></ref><ref id="b5-cpaa-5-013"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghajanian</surname><given-names>C</given-names></name><name><surname>Blank</surname><given-names>SV</given-names></name><name><surname>Goff</surname><given-names>BA</given-names></name><etal/></person-group><article-title>OCEANS: a randomized, double-blind, placebo-controlled phase III trial
of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial
ovarian, primary peritoneal, or fallopian tube cancer</article-title><source>J Clin
Oncol</source><year>2012</year><volume>30</volume><issue>17</issue><fpage>2039</fpage><lpage>2045</lpage><pub-id pub-id-type="pmid">22529265</pub-id></element-citation></ref><ref id="b6-cpaa-5-013"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thibodeaux</surname><given-names>SR</given-names></name><name><surname>Curiel</surname><given-names>TJ</given-names></name></person-group><article-title>Immune therapy for ovarian cancer: promise and
pitfalls</article-title><source>Int Rev
Immunol</source><year>2011</year><volume>30</volume><issue>2&#x02013;3</issue><fpage>102</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">21557637</pub-id></element-citation></ref><ref id="b7-cpaa-5-013"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Butler</surname><given-names>M</given-names></name><name><surname>Oble</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Immunologic and clinical effects of antibody blockade of cytotoxic T
lymphocyte-associated antigen 4 in previously vaccinated cancer patients</article-title><source>Proc
Natl Acad Sci U S
A</source><year>2008</year><volume>105</volume><issue>8</issue><fpage>3005</fpage><lpage>3010</lpage><pub-id pub-id-type="pmid">18287062</pub-id></element-citation></ref><ref id="b8-cpaa-5-013"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Mihm</surname><given-names>MC</given-names></name><name><surname>Soiffer</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Biologic activity of cytotoxic T lymphocyte-associated antigen 4
antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma
patients</article-title><source>Proc Natl Acad Sci U S
A</source><year>2003</year><volume>100</volume><issue>8</issue><fpage>4712</fpage><lpage>4717</lpage><pub-id pub-id-type="pmid">12682289</pub-id></element-citation></ref><ref id="b9-cpaa-5-013"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>RP</given-names></name><name><surname>Gooding</surname><given-names>W</given-names></name><name><surname>Lembersky</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Comparison of toxicity and survival following intraperitoneal
recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus
7-day infusion</article-title><source>J Clin
Oncol</source><year>1997</year><volume>15</volume><issue>11</issue><fpage>3399</fpage><lpage>3407</lpage><pub-id pub-id-type="pmid">9363872</pub-id></element-citation></ref><ref id="b10-cpaa-5-013"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlad</surname><given-names>AM</given-names></name><name><surname>Budiu</surname><given-names>RA</given-names></name><name><surname>Lenzner</surname><given-names>DE</given-names></name><etal/></person-group><article-title>A phase II trial of intraperitoneal interleukin-2 in patients with
platinum-resistant or platinum-refractory ovarian cancer</article-title><source>Cancer Immunol
Immunother</source><year>2010</year><volume>59</volume><issue>2</issue><fpage>293</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">19690855</pub-id></element-citation></ref><ref id="b11-cpaa-5-013"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name></person-group><article-title>Adoptive cell therapy for the treatment of patients with metastatic
melanoma</article-title><source>Curr Opin
Immunol</source><year>2009</year><volume>21</volume><issue>2</issue><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">19304471</pub-id></element-citation></ref><ref id="b12-cpaa-5-013"><label>12</label><element-citation publication-type="journal"><collab>Cancer Genome Atlas Research
Network</collab><article-title>Integrated genomic analyses of ovarian
carcinoma</article-title><source>Nature</source><year>2011</year><volume>474</volume><issue>7353</issue><fpage>609</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">21720365</pub-id></element-citation></ref><ref id="b13-cpaa-5-013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heitz</surname><given-names>F</given-names></name><name><surname>Harter</surname><given-names>P</given-names></name><name><surname>Ewald-Riegler</surname><given-names>N</given-names></name><name><surname>Papsdorf</surname><given-names>M</given-names></name><name><surname>Kommoss</surname><given-names>S</given-names></name><name><surname>du Bois</surname><given-names>A</given-names></name></person-group><article-title>Poly(ADP-ribosyl)ation polymerases: mechanism and new target of
anticancer therapy</article-title><source>Expert Rev Anticancer
Ther</source><year>2010</year><volume>10</volume><issue>7</issue><fpage>1125</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">20645701</pub-id></element-citation></ref><ref id="b14-cpaa-5-013"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ratner</surname><given-names>ES</given-names></name><name><surname>Sartorelli</surname><given-names>AC</given-names></name><name><surname>Lin</surname><given-names>ZP</given-names></name></person-group><article-title>Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored
and personalized therapies for epithelial ovarian cancer</article-title><source>Curr Opin
Oncol</source><year>2012</year><volume>24</volume><issue>5</issue><fpage>564</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">22759740</pub-id></element-citation></ref><ref id="b15-cpaa-5-013"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naumann</surname><given-names>RW</given-names></name><name><surname>Symanowski</surname><given-names>JT</given-names></name><name><surname>Ghamande</surname><given-names>SA</given-names></name><etal/></person-group><article-title>PRECEDENT: a randomized phase II trial comparing EC145 and pegylated
liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant
ovarian cancer</article-title><source>J Clin
Oncol</source><year>2010</year><volume>28</volume><issue>Supplement 18</issue><comment>Available
from: <ext-link ext-link-type="uri" xlink:href="http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA5012b">http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA5012b</ext-link></comment><date-in-citation>Accessed
March 13, 2013</date-in-citation></element-citation></ref><ref id="b16-cpaa-5-013"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stecklein</surname><given-names>SR</given-names></name><name><surname>Kumaraswamy</surname><given-names>E</given-names></name><name><surname>Behbod</surname><given-names>F</given-names></name><etal/></person-group><article-title>BRCA1 and HSP90 cooperate in homologous and non-homologous DNA
double-strandbreak repair and G2/M checkpoint activation</article-title><source>Proc Natl Acad Sci U
S
A</source><year>2012</year><volume>109</volume><issue>34</issue><fpage>13650</fpage><lpage>13655</lpage><pub-id pub-id-type="pmid">22869732</pub-id></element-citation></ref><ref id="b17-cpaa-5-013"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Padilla</surname><given-names>I</given-names></name><name><surname>Clarke</surname><given-names>B</given-names></name><name><surname>Hirte</surname><given-names>H</given-names></name><etal/></person-group><article-title>A phase II study of RO4929097 (RO), a gamma-secretase inhibitor, in
advanced platinum (Pt)- resistant (R) ovarian cancer (OC): a study of the PMH, Chicago, and
California phase II consortia</article-title><source>J Clin
Oncol</source><year>2012</year><volume>30</volume><issue>Suppl</issue><comment>Available from:
<ext-link ext-link-type="uri" xlink:href="https://meetinglibrary.asco.org/content/94913-114">https://meetinglibrary.asco.org/content/94913-114</ext-link></comment><date-in-citation>Accessed March
13, 2013</date-in-citation></element-citation></ref><ref id="b18-cpaa-5-013"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falchook</surname><given-names>GS</given-names></name><name><surname>Goff</surname><given-names>BA</given-names></name><name><surname>Kurzrock</surname><given-names>R</given-names></name><etal/></person-group><article-title>Phase I/II study of weekly paclitaxel with or without MLN8237
(alisertib), an investigational aurora A kinase inhibitor, in patients with recurrent epithelial
ovarian, fallopian tube, or primary peritoneal cancer (OC), or breast cancer (BrC): phase I
results</article-title><source>J Clin
Oncol</source><year>2012</year><volume>30</volume><issue>Suppl</issue><comment>Available from:
<ext-link ext-link-type="uri" xlink:href="http://meetinglibrary.asco.org/content/96468-114">http://meetinglibrary.asco.org/content/96468-114</ext-link></comment><date-in-citation>Accessed March
13, 2013</date-in-citation></element-citation></ref><ref id="b19-cpaa-5-013"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>H</given-names></name></person-group><article-title>Innate immunity&#x02019;s path to the Nobel Prize 2011 and
beyond</article-title><source>Eur J
Immunol</source><year>2012</year><volume>42</volume><issue>5</issue><fpage>1089</fpage><lpage>1092</lpage><pub-id pub-id-type="pmid">22539282</pub-id></element-citation></ref><ref id="b20-cpaa-5-013"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janeway</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><article-title>Innate immune recognition</article-title><source>Annu Rev
Immunol</source><year>2002</year><volume>20</volume><fpage>197</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">11861602</pub-id></element-citation></ref><ref id="b21-cpaa-5-013"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>DS</given-names></name><name><surname>Whiteside</surname><given-names>TL</given-names></name><name><surname>Kanbour</surname><given-names>A</given-names></name><name><surname>Herberman</surname><given-names>RB</given-names></name></person-group><article-title>Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19
(NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian
tumors</article-title><source>J
Immunol</source><year>1988</year><volume>140</volume><issue>11</issue><fpage>4042</fpage><lpage>4049</lpage><pub-id pub-id-type="pmid">3286766</pub-id></element-citation></ref><ref id="b22-cpaa-5-013"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negus</surname><given-names>RP</given-names></name><name><surname>Stamp</surname><given-names>GW</given-names></name><name><surname>Hadley</surname><given-names>J</given-names></name><name><surname>Balkwill</surname><given-names>FR</given-names></name></person-group><article-title>Quantitative assessment of the leukocyte infiltrate in ovarian cancer
and its relationship to the expression of C-C chemokines</article-title><source>Am J
Pathol</source><year>1997</year><volume>150</volume><issue>5</issue><fpage>1723</fpage><lpage>1734</lpage><pub-id pub-id-type="pmid">9137096</pub-id></element-citation></ref><ref id="b23-cpaa-5-013"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Conejo-Garcia</surname><given-names>JR</given-names></name><name><surname>Katsaros</surname><given-names>D</given-names></name><etal/></person-group><article-title>Intratumoral T cells, recurrence, and survival in epithelial ovarian
cancer</article-title><source>N Engl J
Med</source><year>2003</year><volume>348</volume><issue>3</issue><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">12529460</pub-id></element-citation></ref><ref id="b24-cpaa-5-013"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>E</given-names></name><name><surname>Olson</surname><given-names>SH</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><etal/></person-group><article-title>Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high
CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian
cancer</article-title><source>Proc Natl Acad Sci U S
A</source><year>2005</year><volume>102</volume><issue>51</issue><fpage>18538</fpage><lpage>18543</lpage><pub-id pub-id-type="pmid">16344461</pub-id></element-citation></ref><ref id="b25-cpaa-5-013"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scarlett</surname><given-names>UK</given-names></name><name><surname>Cubillos-Ruiz</surname><given-names>JR</given-names></name><name><surname>Nesbeth</surname><given-names>YC</given-names></name><etal/></person-group><article-title>In situ stimulation of CD40 and Toll-like receptor 3 transforms
ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory
cells</article-title><source>Cancer
Res</source><year>2009</year><volume>69</volume><issue>18</issue><fpage>7329</fpage><lpage>7337</lpage><pub-id pub-id-type="pmid">19738057</pub-id></element-citation></ref><ref id="b26-cpaa-5-013"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Gregorio</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Plasmacytoid dendritic cells promote immunosuppression in ovarian
cancer via ICOS costimulation of Foxp3(+) T-regulatory cells</article-title><source>Cancer
Res</source><year>2012</year><volume>72</volume><issue>20</issue><fpage>5240</fpage><lpage>5249</lpage><pub-id pub-id-type="pmid">22850422</pub-id></element-citation></ref><ref id="b27-cpaa-5-013"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fialov&#x000e1;</surname><given-names>A</given-names></name><name><surname>Partlov&#x000e1;</surname><given-names>S</given-names></name><name><surname>Sojka</surname><given-names>L</given-names></name><etal/></person-group><article-title>Dynamics of T-cell infiltration during the course of ovarian cancer:
the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory
T-cells</article-title><source>Int J
Cancer</source><year>2013</year><volume>132</volume><issue>5</issue><fpage>1070</fpage><lpage>1090</lpage><pub-id pub-id-type="pmid">22865582</pub-id></element-citation></ref><ref id="b28-cpaa-5-013"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Jaffee</surname><given-names>EM</given-names></name></person-group><article-title>Regulatory T-cell modulation using cyclophosphamide in vaccine
approaches: a current perspective</article-title><source>Cancer
Res</source><year>2012</year><volume>72</volume><issue>14</issue><fpage>3439</fpage><lpage>3444</lpage><pub-id pub-id-type="pmid">22761338</pub-id></element-citation></ref><ref id="b29-cpaa-5-013"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herber</surname><given-names>DL</given-names></name><name><surname>Nagaraj</surname><given-names>S</given-names></name><name><surname>Djeu</surname><given-names>JY</given-names></name><name><surname>Gabrilovich</surname><given-names>DI</given-names></name></person-group><article-title>Mechanism and therapeutic reversal of immune suppression in
cancer</article-title><source>Cancer
Res</source><year>2007</year><volume>67</volume><issue>11</issue><fpage>5067</fpage><lpage>5069</lpage><pub-id pub-id-type="pmid">17545581</pub-id></element-citation></ref><ref id="b30-cpaa-5-013"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Precopio</surname><given-names>M</given-names></name><name><surname>Lan</surname><given-names>T</given-names></name><etal/></person-group><article-title>Antitumor activity and immune response induction of a dual agonist of
Toll-like receptors 7 and 8</article-title><source>Mol Cancer
Ther</source><year>2010</year><volume>9</volume><issue>6</issue><fpage>1788</fpage><lpage>1797</lpage><pub-id pub-id-type="pmid">20515950</pub-id></element-citation></ref><ref id="b31-cpaa-5-013"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smits</surname><given-names>EL</given-names></name><name><surname>Ponsaerts</surname><given-names>P</given-names></name><name><surname>Berneman</surname><given-names>ZN</given-names></name><name><surname>Van Tendeloo</surname><given-names>VF</given-names></name></person-group><article-title>The use of TLR7 and TLR8 ligands for the enhancement of cancer
immunotherapy</article-title><source>Oncologist</source><year>2008</year><volume>13</volume><issue>8</issue><fpage>859</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">18701762</pub-id></element-citation></ref><ref id="b32-cpaa-5-013"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>TLR signaling</article-title><source>Semin
Immunol</source><year>2007</year><volume>19</volume><issue>1</issue><fpage>24</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">17275323</pub-id></element-citation></ref><ref id="b33-cpaa-5-013"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><etal/></person-group><article-title>Specific recruitment of regulatory T cells in ovarian carcinoma
fosters immune privilege and predicts reduced survival</article-title><source>Nat
Med</source><year>2004</year><volume>10</volume><issue>9</issue><fpage>942</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">15322536</pub-id></element-citation></ref><ref id="b34-cpaa-5-013"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><etal/></person-group><article-title>Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor
immunity</article-title><source>Nat
Med</source><year>2003</year><volume>9</volume><issue>5</issue><fpage>562</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">12704383</pub-id></element-citation></ref><ref id="b35-cpaa-5-013"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>The role of pattern-recognition receptors in innate immunity: update
on Toll-like receptors</article-title><source>Nat
Immunol</source><year>2010</year><volume>11</volume><issue>5</issue><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">20404851</pub-id></element-citation></ref><ref id="b36-cpaa-5-013"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heil</surname><given-names>F</given-names></name><name><surname>Hemmi</surname><given-names>H</given-names></name><name><surname>Hochrein</surname><given-names>H</given-names></name><etal/></person-group><article-title>Species-specific recognition of single-stranded RNA via toll-like
receptor 7 and
8</article-title><source>Science</source><year>2004</year><volume>303</volume><issue>5663</issue><fpage>1526</fpage><lpage>1529</lpage><pub-id pub-id-type="pmid">14976262</pub-id></element-citation></ref><ref id="b37-cpaa-5-013"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>JM</given-names></name><name><surname>Alexopoulou</surname><given-names>L</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><etal/></person-group><article-title>Recognition of single-stranded RNA viruses by Toll-like receptor
7</article-title><source>Proc Natl Acad Sci U S
A</source><year>2004</year><volume>101</volume><issue>15</issue><fpage>5598</fpage><lpage>5603</lpage><pub-id pub-id-type="pmid">15034168</pub-id></element-citation></ref><ref id="b38-cpaa-5-013"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Kandimalla</surname><given-names>ER</given-names></name></person-group><article-title>Synthetic agonists of Toll-like receptors 7, 8 and
9</article-title><source>Biochem Soc Trans</source><year>2007</year><volume>35</volume><issue>Pt
6</issue><fpage>1461</fpage><lpage>1467</lpage><pub-id pub-id-type="pmid">18031246</pub-id></element-citation></ref><ref id="b39-cpaa-5-013"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanzler</surname><given-names>H</given-names></name><name><surname>Barrat</surname><given-names>FJ</given-names></name><name><surname>Hessel</surname><given-names>EM</given-names></name><name><surname>Coffman</surname><given-names>RL</given-names></name></person-group><article-title>Therapeutic targeting of innate immunity with Toll-like receptor
agonists and antagonists</article-title><source>Nat
Med</source><year>2007</year><volume>13</volume><issue>5</issue><fpage>552</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">17479101</pub-id></element-citation></ref><ref id="b40-cpaa-5-013"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Dietsch</surname><given-names>GN</given-names></name><name><surname>Matthews</surname><given-names>MA</given-names></name><etal/></person-group><article-title>VTX-2337 is a novel TLR8 agonist that activates NK cells and augments
ADCC</article-title><source>Clin Cancer
Res</source><year>2012</year><volume>18</volume><issue>2</issue><fpage>499</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">22128302</pub-id></element-citation></ref><ref id="b41-cpaa-5-013"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diebold</surname><given-names>SS</given-names></name></person-group><article-title>Recognition of viral single-stranded RNA by Toll-like
receptors</article-title><source>Adv Drug Deliv
Rev</source><year>2008</year><volume>60</volume><issue>7</issue><fpage>813</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">18241955</pub-id></element-citation></ref><ref id="b42-cpaa-5-013"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>A</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><article-title>Toll-like receptor control of the adaptive immune
responses</article-title><source>Nat
Immunol</source><year>2004</year><volume>5</volume><issue>10</issue><fpage>987</fpage><lpage>995</lpage><pub-id pub-id-type="pmid">15454922</pub-id></element-citation></ref><ref id="b43-cpaa-5-013"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Majewski</surname><given-names>P</given-names></name><etal/></person-group><article-title>The plasticity of dendritic cell responses to pathogens and their
components</article-title><source>Science</source><year>2001</year><volume>294</volume><issue>5543</issue><fpage>870</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">11679675</pub-id></element-citation></ref><ref id="b44-cpaa-5-013"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>IH</given-names></name><name><surname>Smolle</surname><given-names>J</given-names></name><name><surname>Binder</surname><given-names>B</given-names></name><name><surname>Cerroni</surname><given-names>L</given-names></name><name><surname>Richtig</surname><given-names>E</given-names></name><name><surname>Kerl</surname><given-names>H</given-names></name></person-group><article-title>Topical imiquimod in the treatment of metastatic melanoma to
skin</article-title><source>Arch
Dermatol</source><year>2003</year><volume>139</volume><issue>3</issue><fpage>273</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">12622616</pub-id></element-citation></ref><ref id="b45-cpaa-5-013"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majewski</surname><given-names>S</given-names></name><name><surname>Marczak</surname><given-names>M</given-names></name><name><surname>Mlynarczyk</surname><given-names>B</given-names></name><name><surname>Benninghoff</surname><given-names>B</given-names></name><name><surname>Jablonska</surname><given-names>S</given-names></name></person-group><article-title>Imiquimod is a strong inhibitor of tumor cell-induced
angiogenesis</article-title><source>Int J
Dermatol</source><year>2005</year><volume>44</volume><issue>1</issue><fpage>14</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">15663652</pub-id></element-citation></ref><ref id="b46-cpaa-5-013"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korman</surname><given-names>N</given-names></name><name><surname>Moy</surname><given-names>R</given-names></name><name><surname>Ling</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dosing with 5% imiquimod cream 3 times per week for the
treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group,
vehicle-controlled trials</article-title><source>Arch
Dermatol</source><year>2005</year><volume>141</volume><issue>4</issue><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">15837864</pub-id></element-citation></ref><ref id="b47-cpaa-5-013"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Girardi</surname><given-names>M</given-names></name><name><surname>Duvic</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG
7909), in patients with treatment- refractory, cutaneous T-cell lymphoma</article-title><source>J Am
Acad
Dermatol</source><year>2010</year><volume>63</volume><issue>6</issue><fpage>975</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">20888065</pub-id></element-citation></ref><ref id="b48-cpaa-5-013"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zent</surname><given-names>CS</given-names></name><name><surname>Smith</surname><given-names>BJ</given-names></name><name><surname>Ballas</surname><given-names>ZK</given-names></name><etal/></person-group><article-title>Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in
patients with previously treated chronic lymphocytic leukemia</article-title><source>Leuk
Lymphoma</source><year>2012</year><volume>53</volume><issue>2</issue><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">21812536</pub-id></element-citation></ref><ref id="b49-cpaa-5-013"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Kiniwa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Toll-like receptor 8-mediated reversal of CD4+ regulatory T
cell
function</article-title><source>Science</source><year>2005</year><volume>309</volume><issue>5739</issue><fpage>1380</fpage><lpage>1384</lpage><pub-id pub-id-type="pmid">16123302</pub-id></element-citation></ref><ref id="b50-cpaa-5-013"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Uematsu</surname><given-names>S</given-names></name><name><surname>Takeuchi</surname><given-names>O</given-names></name></person-group><article-title>Pathogen recognition and innate
immunity</article-title><source>Cell</source><year>2006</year><volume>124</volume><issue>4</issue><fpage>783</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">16497588</pub-id></element-citation></ref><ref id="b51-cpaa-5-013"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorski</surname><given-names>KS</given-names></name><name><surname>Waller</surname><given-names>EL</given-names></name><name><surname>Bjornton-Severson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Distinct indirect pathways govern human NK-cell activation by TLR-7
and TLR-8 agonists</article-title><source>Int
Immunol</source><year>2006</year><volume>18</volume><issue>7</issue><fpage>1115</fpage><lpage>1126</lpage><pub-id pub-id-type="pmid">16728430</pub-id></element-citation></ref><ref id="b52-cpaa-5-013"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamm</surname><given-names>S</given-names></name><name><surname>Rath</surname><given-names>S</given-names></name><name><surname>Michel</surname><given-names>S</given-names></name><name><surname>Baumgartner</surname><given-names>R</given-names></name></person-group><article-title>Cancer immunotherapeutic potential of novel small molecule TLR7 and
TLR8 agonists</article-title><source>J
Immunotoxicol</source><year>2009</year><volume>6</volume><issue>4</issue><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">19848448</pub-id></element-citation></ref><ref id="b53-cpaa-5-013"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>McFarland-Mancini</surname><given-names>MM</given-names></name><name><surname>Funk</surname><given-names>HM</given-names></name><name><surname>Husseinzadeh</surname><given-names>N</given-names></name><name><surname>Mounajjed</surname><given-names>T</given-names></name><name><surname>Drew</surname><given-names>AF</given-names></name></person-group><article-title>Toll-like receptor expression in normal ovary and ovarian
tumors</article-title><source>Cancer Immunol
Immunother</source><year>2009</year><volume>58</volume><issue>9</issue><fpage>1375</fpage><lpage>1385</lpage><pub-id pub-id-type="pmid">19184006</pub-id></element-citation></ref><ref id="b54-cpaa-5-013"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casares</surname><given-names>N</given-names></name><name><surname>Pequignot</surname><given-names>MO</given-names></name><name><surname>Tesniere</surname><given-names>A</given-names></name><etal/></person-group><article-title>Caspase-dependent immunogenicity of doxorubicin-induced tumor cell
death</article-title><source>J Exp
Med</source><year>2005</year><volume>202</volume><issue>12</issue><fpage>1691</fpage><lpage>1701</lpage><pub-id pub-id-type="pmid">16365148</pub-id></element-citation></ref><ref id="b55-cpaa-5-013"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obeid</surname><given-names>M</given-names></name><name><surname>Tesniere</surname><given-names>A</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><etal/></person-group><article-title>Calreticulin exposure dictates the immunogenicity of cancer cell
death</article-title><source>Nat
Med</source><year>2007</year><volume>13</volume><issue>1</issue><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">17187072</pub-id></element-citation></ref><ref id="b56-cpaa-5-013"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>PA</given-names></name><name><surname>Northfelt</surname><given-names>DW</given-names></name><name><surname>Weiss</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Phase I clinical trial of VTX- 2337, a selective toll-like receptor 8
(TLR8) agonist, in patients with advanced solid tumors</article-title><source>J Clin
Oncol</source><year>2011</year><volume>29</volume><issue>Suppl 15</issue><comment>Available from:
<ext-link ext-link-type="uri" xlink:href="http://meeting.ascopubs.org/cgi/content/short/29/15_suppl/2537?rss=1">http://meeting.ascopubs.org/cgi/content/short/29/15_suppl/2537?rss=1</ext-link></comment><date-in-citation>Accessed
March 13, 2013</date-in-citation></element-citation></ref><ref id="b57-cpaa-5-013"><label>57</label><element-citation publication-type="book"><collab>Clinical Oncology Group</collab><article-title>A phase I study
of VTX-2337 (IND #78,416) in combination with Doxil<sup>&#x000ae;</sup>(NSC# 712227)
in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal
cancer</article-title><source>ClinicalTrialsgov [website on the
Internet]</source><publisher-loc>Bethesda, MD</publisher-loc><publisher-name>US National
Library of Medicine</publisher-name><year>2011</year><comment>[updated June 15,
2012]. Available from: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01294293">http://clinicaltrials.gov/show/NCT01294293</ext-link>. NLM identifier:
NCT01294293</comment><date-in-citation>Accessed March 13, 2013</date-in-citation></element-citation></ref><ref id="b58-cpaa-5-013"><label>58</label><element-citation publication-type="book"><collab>Clinical Oncology Group</collab><article-title>A randomized,
double-blind, placebo-controlled phase II Study of VTX-2337 in combination with pegylated liposomal
doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or
primary peritoneal cancer</article-title><source>ClinicalTrialsgov [website on the
Internet]</source><publisher-loc>Bethesda, MD</publisher-loc><publisher-name>US National
Library of Medicine</publisher-name><year>2012</year><comment>[updated March 7,
2013]. Available from: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/show/NCT01666444">http://clinicaltrials.gov/show/NCT01666444</ext-link>. NLM identifier:
NCT01666444</comment><date-in-citation>Accessed March 13, 2013</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig id="f1-cpaa-5-013" position="float"><label>Figure 1</label><caption><p>Schema of some of the hypothesized effects of the administration of VTX- 2337 and pegylated
doxorubicin resulting in the activation of multiple components of innate immunity, including
immunosuppressive regulatory T cells (Tregs), tumor cellsnatural killer cells (NK), dendritic cells
(DC), and monocytes (MC), and the secretion of multiple cytokines. </p><p><bold>Notes:</bold> These changes in the microenvironment may lead to increased tumor cell death. </p><p><bold>Abbreviations:</bold> IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.</p></caption><graphic xlink:href="cpaa-5-013f1"/></fig><fig id="f2-cpaa-5-013" position="float"><label>Figure 2</label><caption><p>Schema of Gynecologic Oncology Group (GOG) partners trial 3003. </p><p><bold>Notes:</bold> Response Evaluation Criteria in Solid Tumors (RECIST)<sup>60</sup>
</p><p><bold>Abbreviations:</bold> IV, intravenous; q, every.</p></caption><graphic xlink:href="cpaa-5-013f2"/></fig><table-wrap id="t1-cpaa-5-013" position="float"><label>Table 1</label><caption><p>Breakdown of Toll-like receptors: their cellular expression, intracellular location, natural
ligands.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Cellular expression<xref ref-type="bibr" rid="b30-cpaa-5-013">30</xref>,<xref ref-type="bibr" rid="b35-cpaa-5-013">35</xref>,<xref ref-type="bibr" rid="b40-cpaa-5-013">40</xref>,<xref ref-type="bibr" rid="b41-cpaa-5-013">41</xref>,<sup>59</sup></th><th align="left" valign="top" rowspan="1" colspan="1">Location within cell<xref ref-type="bibr" rid="b36-cpaa-5-013">36</xref>&#x02013;<xref ref-type="bibr" rid="b38-cpaa-5-013">38</xref></th><th align="left" valign="top" rowspan="1" colspan="1">Natural ligand<xref ref-type="bibr" rid="b39-cpaa-5-013">39</xref></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR1</td><td align="left" valign="top" rowspan="1" colspan="1">Monocyte, mDC, B cell, NK, neutrophil, basophil</td><td align="left" valign="top" rowspan="1" colspan="1">Cell membrane</td><td align="left" valign="top" rowspan="1" colspan="1">Triacyl lipopeptide</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR2</td><td align="left" valign="top" rowspan="1" colspan="1">Monocyte, mastocytes, mDC</td><td align="left" valign="top" rowspan="1" colspan="1">Cell membrane</td><td align="left" valign="top" rowspan="1" colspan="1">Triacyl lipopeptide, lipoteichoic acid, zymosan, porins,
macrophage-activating lipopeptide, bacterial peptidoglycan, lipoarabinomannan</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR3</td><td align="left" valign="top" rowspan="1" colspan="1">mDC</td><td align="left" valign="top" rowspan="1" colspan="1">Endosomal membrane</td><td align="left" valign="top" rowspan="1" colspan="1">dsDNA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR4</td><td align="left" valign="top" rowspan="1" colspan="1">Monocytes, macrophages, mDC, mastocytes, basophil</td><td align="left" valign="top" rowspan="1" colspan="1">Cell membrane</td><td align="left" valign="top" rowspan="1" colspan="1">LPS, mannan, phospholipds, envelope proteins</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR5</td><td align="left" valign="top" rowspan="1" colspan="1">mDC, monocyte, NK, T cell</td><td align="left" valign="top" rowspan="1" colspan="1">Cell membrane</td><td align="left" valign="top" rowspan="1" colspan="1">Flagellin</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR6</td><td align="left" valign="top" rowspan="1" colspan="1">Monocyte, mastocytes, mDC</td><td align="left" valign="top" rowspan="1" colspan="1">Cell membrane</td><td align="left" valign="top" rowspan="1" colspan="1">Triacyl lipopeptide, lipoteichoic acid, zymosan, porins,
macrophage-activating lipopeptide, bacterial peptidoglycan, lipoarabinomannan</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR 7</td><td align="left" valign="top" rowspan="1" colspan="1">pDC, eosinophil</td><td align="left" valign="top" rowspan="1" colspan="1">Endosomal membrane</td><td align="left" valign="top" rowspan="1" colspan="1">ssRNA (viral)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR8</td><td align="left" valign="top" rowspan="1" colspan="1">mDC, T and B cells, eosinophils, monocytes</td><td align="left" valign="top" rowspan="1" colspan="1">Endosomal membrane</td><td align="left" valign="top" rowspan="1" colspan="1">ssRNA (viral)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR9</td><td align="left" valign="top" rowspan="1" colspan="1">pDC, B cells, basophil, eosinophil</td><td align="left" valign="top" rowspan="1" colspan="1">Endosomal membrane</td><td align="left" valign="top" rowspan="1" colspan="1">DNA (bacterial/viral)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR10</td><td align="left" valign="top" rowspan="1" colspan="1">pDC, neutrophil, B cell, basophil</td><td align="left" valign="top" rowspan="1" colspan="1">Cell membrane</td><td align="left" valign="top" rowspan="1" colspan="1">Unknown</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-cpaa-5-013"><p><bold>Abbreviations:</bold> DNA, deoxyribonucleic acid; dsDNA, double-stranded DNA; LPS,
lipopolysaccharide; mDC, myeloid dendritic cells; NK, natural killer cells; pDC, plasmatoid
dendritic cells; ssRNA, single stranded ribonucleic acid; TLR, Toll-like receptors.</p></fn></table-wrap-foot></table-wrap></floats-group></article>